Enhancement of transdermal delivery of tamoxifen citrate using nanoemulsion vehicle

International Journal of PharmTech Research

Volumn 3, Issue 1, 2011, Pages 287-297

  Pathan, Inayat Bashir ^a   Mallikarjuna Setty, C ^b  

^a UNIVERSITY OF PUNE   (India)

^b Saraswathi College of Pharmaceutical Sciences   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIS OIL; SURFACTANT; TAMOXIFEN CITRATE;

ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; FOURIER TRANSFORM MASS SPECTROMETRY; MALE; NANOEMULSION; NONHUMAN; PARTICLE SIZE; RAT; REFRACTION INDEX; SKIN IRRITATION TEST; SKIN PENETRATION; SKIN TEST; THERMODYNAMICS; TRANSMISSION ELECTRON MICROSCOPY;

EID: 79951558812     PISSN: None     EISSN: 09744304     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Clarke R, Liu MC and Bouker K B., Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling, Oncogene., 2003, 22, 7316-7339.
2. Jordan VC, Murphy CS, Endocrine pharmacology of antiestrogens as antitumor agents, Endocr. Rev., 1990, 11, 49-81.
3. Furr BJ, Jordan VC. The pharmacology and clinical uses of tamoxifen, Pharm. Ther. 1984,25,127-205.
4. Morrow, M., and Jordan V C., Risk factors and the prevention of breast cancer with tamoxifen. In Cancer Surveys: Breast cancer, ed. JT Papademitrio, I Fentiman, Imperial Res. Fund. London: Cold Spring Harbor Lab. Press, 1993,18, 211-229.
5. Jordan VC., Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. Annu Rev Pharmacol Toxicol, 1995, 35, 195-211.
6. Brigger I, Chaminade P, Marsaud V, Appel M, Besnard M, Gurny R, Renoir M. and Couvreur, P., Tamoxifen encapsulation within polyethylene glycol-coated nanospheres. A new antiestrogen formulation. Int J Pharm, 2001,214, 37-42.
7. Guy RH, Current status and future prospects of transdermal drug delivery. Pharm. Res. 1996, 13, 1765-1769.
8. Nielsen FS, Petersen KB, llertz AM,. Bioavailability of probucol from lipid and surfactant based formulations in minipigs: influence of droplet size and dietary state. Eur. J. Pharm. Biopharm., 2008,69, 553-562.
9. Schwendener RA, Schott H. Lipophilic 1-beta-darabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model. J. Cancer Res. Clin. Oncol.,1996, 122, 723-726.
10. Gursoya RN, Benita S,. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed. Pharmacother. 2004,58,173-182.
11. Osborne DW, Ward A J. and Neil K J., Microemulsions as topical delivery vehicles: invitro transdermal studies of a model hydrophilic drug, J. Pharm. Phamacol.1991,43,450-454.
12. Trotta M, Pattarino F. and Gasco MR, Influence of counter ions on the skin permeation of methotrexate from water-oil microemulsions, Pharm. Acta. Helv.1996 71,135-140.
13. Shafiq S, Faiyaz S., Sushma T., Farhan JA, Khar RK. and Ali M., Design and development of ramipril nanoemulsion formulation: In vitro and in vivo assessment, J. Biomed. Nanotechnol. 2007,328-344.
14. Shafiq S, Faiyaz S, Sushma T, Farhan JA. Khar, RK and Ali M., Development and bioavailability assessment of ramipril nanoemulsion formulation, Eur. J. Pharm. Biopharm. 2007, 66, 227-243.
15. Hiemenz PC and Rajgopalan R., In: Principles of colloidal and surface chemistry, 3rd edition, Marcel Dekker, New York, 1997,389.
16. Dixit N, Kohli K, Baboota S. Nanoemulsion system for the transdermal delivery of a poorly soluble cardiovascular drug. PDA J. Pharm. Sci. Technol., 2008, 62, 46.
17. Khandavilli S, Panchagnula R. Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats. J. Invest. Dermatol., 2007, 127, 154.
18. Shevachman M, Garti N, Shani A, Sintov A.C. Enhanced percutaneous permeability of diclofenac using a new U-type dilutable microemulsion. Drug Dev. Ind. Pharm., 2008, 34, 403.
19. Baboota S, Al-Azaki A, Kohli K, Ali J, Dixit N, Shakeel F. Development and evaluation of a microemulsion formulation for transdermal delivery of terbinafine. PDA J. Pharm Sci. Technol., 2007, 61, 276.
20. Kantarci G, Ozgüney I, Karasulu HY, Arzi S, Güneri T. Comparison of different water/oil microemulsions containing diclofenac sodium: preparation, characterization, release rate, and skin irritation studies. AAPS Pharm. Sci. Tech., 2007, 8, E91.
21. Huang YB, Lin YH, Lu TM, Wang RJ, Tsai YH, Wu PC. Transdermal delivery of capsaicin derivative-sodium nonivamide acetate using microemulsions as vehicles. Int. J. Pharm., 2008, 349, 206.
22. Junyaprasert VB, Boonsaner P, Leatwimonlak S, Boonme P. Enhancement of the skin permeation of clindamycin phosphate by Aerosol OT/1- butanol microemulsions. Drug Dev. Ind. Pharm., 2007, 33, 874.
23. Junyaprasert VB, Boonme P, Songkro S, Krauel K, Rades T. Transdermal delivery of hydrophobic and hydrophilic local anesthetics from o/w and w/o Brij 97-based microemulsions. J. Pharm. Pharm. Sci., 2007, 10, 288.
24. Kamal MA, Iimura N, Nabekura T, Kitagawa S. Enhanced skin permeation of diclofenac by ionpair formation and further enhancement by microemulsion. Chem. Pharm. Bull., 2007, 55, 368.
25. Lee PJ, Langer R, Shastri VP. Novel microemulsion enhancer formulation for simultaneous transdermal delivery of hydrophilic and hydrophobic drugs. Pharm. Res, 2003, 20, 264.
26. Yuan JS, Ansari M, Samaan, M, Acosta EJ. Linker-based lecithin microemulsions for transdermal delivery of lidocaine. Int. J. Pharm., 2008, 349, 130.
27. Yuan Y, Li SM, Mo FK, Zhong DF. Investigation of microemulsion system for transdermal delivery of meloxicam. Int. J. Pharm., 2006, 321,117.
28. Biruss B, Kählig H, Valenta C. Evaluation of an eucalyptus oil containing topical drug delivery system for selected steroid hormones. Int. J. Pharm., 2007, 328, 142
29. Shevachman M, Garti N, Shani A, Sintov AC. Enhanced percutaneous permeability of diclofenac using a new U-type dilutable microemulsion. Drug Dev. Ind. Pharm., 2008, 34, 403.
30. Shakeel F, Baboota S, Ahuja A, Ali J, Aqil M, Shafiq S. Nanoemulsions as vehicles for transdermal delivery of aceclofenac. AAPS Pharm. Sci. Tech., 2007, 8, E104.
31. Ambade KW, Jadhav SL, Gambhire MN, Kurmi SD, Kadam VJ, Jadhav KR. Formulation and evaluation of flurbiprofen microemulsion. Curr. Drug Deliv., 2008, 5, 32.
32. Zhao X, Liu JP, Zhang X, Li Y. Enhancement of transdermal delivery of theophylline using microemulsion vehicle. Int. J. Pharm., 2006, 327, 58.
33. Paolino D, Ventura CA, Nisticò, S, Puglisi G, Fresta M. Lecithin microemulsions for the topical administration of ketoprofen: percutaneous adsorption through human skin and in vivo human skin tolerability. Int. J. Pharm., 2002, 244, 21.
34. Prapaporn B, Karen K, Anja G, Thomas R, Varaporn, B J. Characterization of microemulsion structures in the pseudoternary phase diagram of isopropyl palmitate/water/Brij 97:1-butanol. AAPS Pharm- SciTech., 2006, 7(2), E1-E6.
35. Pathan I.B, Setty C M, Gupta V.R.M. Comparison of the effect of essential oils on the permeation of diclofenac diethylamine through various barriers, Acta Pharmaceutica Sciencia.2008, 50,219-228.
36. Namdeo A, Jain NK. Liquid crystalline pharmacogel based enhanced transdermal deliveryof propranolol hydrochloride. J Control Release.2002,82,223-236.
37. Mutalik S, Udupa N. Glibenclamide transdermal patches: physicochemical, pharmacodynamic, and pharmacokinetic evaluations. J Pharm Sci. 2004,93,1577-1594.
38. Amit Bhatia, Rajiv Kumar, Om Prakash Katare. Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation. J Pharm Pharmaceut Sci. 2004,7(2),252-259.
39. Thacrodi D, Panduranga RK, Transdermal absorption of nifedipine from microemulsions of lipophilic skin penetration enhancers, Int. J. Pharm.1994,111, 235-240.
40. Draize JH, Woodward G, Calvery HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther. 1944, 82,377-379.